Literature DB >> 27957179

Lone AF: is There a Rationale?

Duygu Kocyigit1, Kadri Murat Gurses1, Kudret Aytemir1.   

Abstract

Although atrial fibrillation (AF) development has been demonstrated to be associated with underlying cardiovascular conditions such as hypertension, valvular heart disease or diabetes mellitus; in a subset of relatively younger patients, no cardiopulmonary disease diagnosis can be established. AF patients younger than 60 years without clinical or echocardiographic evidence of cardiopulmonary disease are defined as lone AF patients. Despite the decrease in lone AF prevalence due to advances in understanding of AF pathogenesis, there are still issues yet to be resolved. Future studies are needed to demonstrate the cost- effectiveness of the routine use of more advanced diagnostic tools, such as non- invasive assessment of endothelial function, autoimmune markers or genetic screening and whether they would have clinical implications on treatment of lone AF. This review focuses on the suggested mechanisms in lone AF initiation and maintenance.

Entities:  

Year:  2015        PMID: 27957179      PMCID: PMC5135118          DOI: 10.4022/jafib.1246

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  74 in total

1.  Lone auricular fibrillation.

Authors:  W EVANS; P SWANN
Journal:  Br Heart J       Date:  1954-04

2.  Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications.

Authors:  Hans Kottkamp
Journal:  J Cardiovasc Electrophysiol       Date:  2012-05-03

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

4.  The relationship between personality, socio-economic factors, acute life stress and the development, spontaneous conversion and recurrences of acute lone atrial fibrillation.

Authors:  Anna Vittoria Mattioli; Silvia Bonatti; Mauro Zennaro; Giorgio Mattioli
Journal:  Europace       Date:  2005-05       Impact factor: 5.214

5.  Alcohol and risk of atrial fibrillation or flutter: a cohort study.

Authors:  Lars Frost; Peter Vestergaard
Journal:  Arch Intern Med       Date:  2004-10-11

6.  [Autoantibodies Against beta(1)-Adrenoreceptors in Patients With Cardiac Rhythm Disorders. Prevalence and Possible Role in Development of Arrhythmia].

Authors:  D S Novikova; M S Bekbosynova; T Ia Antidze; N V Loladze; S P Domogatskiĭ; S P Golitsyn; E L Nasonov; I A Denisova; S P Tonevitskiĭ
Journal:  Kardiologiia       Date:  2004       Impact factor: 0.395

7.  Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation.

Authors:  Emmanuel I Skalidis; Michalis I Hamilos; Ioannis K Karalis; Gregory Chlouverakis; George E Kochiadakis; Panos E Vardas
Journal:  J Am Coll Cardiol       Date:  2008-05-27       Impact factor: 24.094

Review 8.  New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'.

Authors:  Bas A Schoonderwoerd; Marcelle D Smit; Lucas Pen; Isabelle C Van Gelder
Journal:  Europace       Date:  2008-05-13       Impact factor: 5.214

9.  Alcohol-related acute atrial fibrillation. A case-control study and review of 40 patients.

Authors:  E C Rich; C Siebold; B Campion
Journal:  Arch Intern Med       Date:  1985-05

10.  Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation.

Authors:  Changhong Zou; Zhiyong Zhang; Wenmin Zhao; Guang Li; Guiling Ma; Xinchun Yang; Jianjun Zhang; Lin Zhang
Journal:  J Transl Med       Date:  2013-01-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.